These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6737271)

  • 41. The stereoselectivity of the 'single drug binding site' of human alpha 1-acid glycoprotein (orosomucoid).
    Brunner F; Müller WE
    J Pharm Pharmacol; 1987 Dec; 39(12):986-90. PubMed ID: 2894446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison between two methods for the determination of the total and free (R)- and (S)-disopyramide in plasma using an alpha 1-acid glycoprotein column.
    Enquist M; Hermansson J
    J Chromatogr; 1989 Sep; 494():143-56. PubMed ID: 2584312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of electrocardiographic response and disposition of R- and S-disopyramide in the rabbit.
    Huang JD; Oie S
    Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):227-41. PubMed ID: 6635318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Drug binding analysis of human alpha 1-acid glycoprotein using capillary electrophoresis].
    Kuroda Y; Shibukawa A; Nakagawa T
    Yakugaku Zasshi; 2003 Sep; 123(9):781-8. PubMed ID: 14513769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Species-dependent binding of disopyramide enantiomers.
    Lima JJ
    Drug Metab Dispos; 1988; 16(4):563-7. PubMed ID: 2903024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1988; 35(3):313-7. PubMed ID: 3181285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A simple method for the simulation of unbound serum disopyramide concentration in patients.
    Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
    J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered protein binding of disopyramide in plasma from patients with cancer and with inflammatory disease.
    Echizen H; Saima S; Umeda N; Ishizaki T
    Ther Drug Monit; 1987 Sep; 9(3):272-8. PubMed ID: 3672569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs.
    Goolkasian DL; Slaughter RL; Edwards DJ; Lalka D
    Eur J Clin Pharmacol; 1983; 25(3):413-7. PubMed ID: 6628530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipophilicity Influences Drug Binding to α1-Acid Glycoprotein F1/S Variants But Not to the A Variant.
    Hanada K
    Drugs R D; 2017 Sep; 17(3):475-480. PubMed ID: 28646384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
    Kishino S; Nomura A; Itoh S; Nakagawa T; Takekuma Y; Sugawara M; Furukawa H; Todo S; Miyazaki K
    Eur J Clin Pharmacol; 2002 Dec; 58(9):621-8. PubMed ID: 12483455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation.
    Lima JJ; MacKichan JJ; Libertin N; Sabino J
    J Pharmacokinet Biopharm; 1983 Oct; 11(5):483-98. PubMed ID: 6668555
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of selective competitive binding of basic drugs to alpha1-acid glycoprotein variants.
    Ishizaki J; Fukaishi A; Fukuwa C; Yamazaki S; Tabata M; Ishida T; Suga Y; Arai K; Yokogawa K; Miyamoto K
    Biol Pharm Bull; 2010; 33(1):95-9. PubMed ID: 20045943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in plasma binding of drugs between Caucasians and Chinese subjects.
    Zhou HH; Adedoyin A; Wilkinson GR
    Clin Pharmacol Ther; 1990 Jul; 48(1):10-7. PubMed ID: 2369804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitory effect of phenothiazines on the binding of [3H]perazine to alpha 1-acid glycoprotein.
    Schley J
    J Pharm Pharmacol; 1987 Feb; 39(2):132-4. PubMed ID: 2881999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stereoselective binding of disopyramide to human plasma protein.
    Lima JJ; Jungbluth GL; Devine T; Robertson LW
    Life Sci; 1984 Aug; 35(8):835-9. PubMed ID: 6482678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of fluorescence immunoassay for total and unbound serum concentrations of disopyramide.
    Lima JJ; Shields BJ; Howell LH; MacKichan JJ
    Ther Drug Monit; 1984; 6(2):203-10. PubMed ID: 6377599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
    Shaw LM; Doherty JU; Waxman HL; Josephson ME
    Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Binding of several phenothiazine neuroleptics to a common binding site of alpha 1-acid glycoprotein, orosomucoid.
    El-Gamal S; Wollert U; Müller WE
    J Pharm Sci; 1983 Feb; 72(2):202-5. PubMed ID: 6131996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs.
    Morse DS; Abernethy DR; Greenblatt DJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):535-9. PubMed ID: 3934087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.